Drug intelligence / Profile preview

CVG201 Lead 3

Development stage: Preclinical
Lead developer: ConverGene
Modality: Small Molecules

Overview

CVG201 Lead 3 is a small molecule inhibitor of BET (Bromodomain and Extra-Terminal motif) proteins currently in preclinical development by ConverGene. As part of the CVG201 internal development program, Lead 3 is specifically being optimized for the treatment of orphan indications. BET proteins act as epigenetic readers that recognize acetylated lysine residues on histones, thereby recruiting transcription factors to regulate the expression of genes associated with cell growth and survival. By targeting these bromodomains, CVG201 Lead 3 aims to disrupt aberrant transcriptional programs underlying rare diseases.

Targets

BET (BET family proteins)

Beyond the preview

Go deeper on CVG201 Lead 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVG201 Lead 3.

Explore the full profile